# Aldeyra Therapeutics, Inc.: financial statements, quarterly

ALDX · Nasdaq · CIK 1341235 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/aldx.md) · [Financials](/companies/aldx/financials.md) · [Filings](/companies/aldx/filings.md) · [Insiders](/companies/aldx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/aldx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [7.0](/filings/0000950170-24-123248.md) | [4.3 d](/filings/0000950170-25-030102.md) | [6.2](/filings/0000950170-25-071602.md) | [15.0](/filings/0000950170-25-104971.md) | [12.4](/filings/0001193125-25-266989.md) | [14.6 d](/filings/0001193125-26-083012.md) | [7.4](/filings/0001341235-26-000006.md) | [8.5](/filings/0001341235-26-000010.md) | [5.4](/filings/0001193125-25-266989.md) | [4.3 d](/filings/0001193125-26-083012.md) | [2.4](/filings/0001341235-26-000006.md) | [3.5](/filings/0001341235-26-000010.md) |
| Operating income | $m | [(9.6)](/filings/0000950170-24-123248.md) | [(6.1) d](/filings/0000950170-25-030102.md) | [(9.4)](/filings/0000950170-25-071602.md) | [(18.0)](/filings/0000950170-25-104971.md) | [(16.1)](/filings/0001193125-25-266989.md) | [(16.6) d](/filings/0001193125-26-083012.md) | [(10.4)](/filings/0001341235-26-000006.md) | [(10.2)](/filings/0001341235-26-000010.md) | [(8.0)](/filings/0001193125-25-266989.md) | [(6.7) d](/filings/0001193125-26-083012.md) | [(3.5)](/filings/0001341235-26-000006.md) | [(5.9)](/filings/0001341235-26-000010.md) |
| Interest expense | $m | [0.5](/filings/0000950170-23-058829.md) | [0.5 d](/filings/0000950170-24-027933.md) | [0.5](/filings/0000950170-24-052056.md) | [0.5](/filings/0000950170-24-089238.md) | [0.5](/filings/0001193125-25-266989.md) | [0.5 d](/filings/0001193125-26-083012.md) | [0.5](/filings/0001341235-26-000006.md) | [0.5](/filings/0001341235-26-000010.md) | [0.5](/filings/0001193125-25-266989.md) | [0.5 d](/filings/0001193125-26-083012.md) | [0.5](/filings/0001341235-26-000006.md) | [0.0](/filings/0001341235-26-000010.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(8.2)](/filings/0000950170-24-123248.md) | [(4.8) d](/filings/0000950170-25-030102.md) | [(8.1)](/filings/0000950170-25-071602.md) | [(16.8)](/filings/0000950170-25-104971.md) | [(15.1)](/filings/0001193125-25-266989.md) | [(15.8) d](/filings/0001193125-26-083012.md) | [(9.9)](/filings/0001341235-26-000006.md) | [(9.8)](/filings/0001341235-26-000010.md) | [(7.7)](/filings/0001193125-25-266989.md) | [(6.5) d](/filings/0001193125-26-083012.md) | [(3.5)](/filings/0001341235-26-000006.md) | [(5.5)](/filings/0001341235-26-000010.md) |
| Diluted EPS | $ per share | [(0.14)](/filings/0000950170-24-123248.md) | not reported | [(0.14)](/filings/0000950170-25-071602.md) | [(0.28)](/filings/0000950170-25-104971.md) | [(0.25)](/filings/0001193125-25-266989.md) | not reported | [(0.17)](/filings/0001341235-26-000006.md) | [(0.16)](/filings/0001341235-26-000010.md) | [(0.13)](/filings/0001193125-25-266989.md) | not reported | [(0.06)](/filings/0001341235-26-000006.md) | [(0.09)](/filings/0001341235-26-000010.md) |
| Basic EPS | $ per share | [(0.14)](/filings/0000950170-24-123248.md) | not reported | [(0.14)](/filings/0000950170-25-071602.md) | [(0.28)](/filings/0000950170-25-104971.md) | [(0.25)](/filings/0001193125-25-266989.md) | not reported | [(0.17)](/filings/0001341235-26-000006.md) | [(0.16)](/filings/0001341235-26-000010.md) | [(0.13)](/filings/0001193125-25-266989.md) | not reported | [(0.06)](/filings/0001341235-26-000006.md) | [(0.09)](/filings/0001341235-26-000010.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | [102](/filings/0000950170-24-052056.md) | [71.0](/filings/0000950170-24-089238.md) | [68.1](/filings/0000950170-24-123248.md) | [54.5](/filings/0001193125-26-083012.md) | [50.4](/filings/0000950170-25-071602.md) | [41.2](/filings/0000950170-25-104971.md) | [59.3](/filings/0001193125-25-266989.md) | [70.0](/filings/0001193125-26-083012.md) | not reported | not reported |
| Current assets | $m | [147](/filings/0000950170-23-058829.md) | [148](/filings/0000950170-25-030102.md) | [141](/filings/0000950170-24-052056.md) | [126](/filings/0000950170-24-089238.md) | [117](/filings/0000950170-24-123248.md) | [104](/filings/0001193125-26-083012.md) | [92.7](/filings/0000950170-25-071602.md) | [84.6](/filings/0000950170-25-104971.md) | [77.5](/filings/0001193125-25-266989.md) | [71.8](/filings/0001341235-26-000010.md) | [66.3](/filings/0001341235-26-000006.md) | [47.4](/filings/0001341235-26-000010.md) |
| Total assets | $m | [147](/filings/0000950170-23-058829.md) | [148](/filings/0000950170-25-030102.md) | [141](/filings/0000950170-24-052056.md) | [126](/filings/0000950170-24-089238.md) | [117](/filings/0000950170-24-123248.md) | [105](/filings/0001193125-26-083012.md) | [93.2](/filings/0000950170-25-071602.md) | [85.0](/filings/0000950170-25-104971.md) | [77.8](/filings/0001193125-25-266989.md) | [72.1](/filings/0001341235-26-000010.md) | [66.5](/filings/0001341235-26-000006.md) | [47.5](/filings/0001341235-26-000010.md) |
| Current liabilities | $m | [21.6](/filings/0000950170-23-058829.md) | [22.3](/filings/0000950170-25-030102.md) | [21.7](/filings/0000950170-24-052056.md) | [27.6](/filings/0000950170-24-089238.md) | [17.2](/filings/0000950170-24-123248.md) | [18.6](/filings/0001193125-26-083012.md) | [14.3](/filings/0000950170-25-071602.md) | [29.5](/filings/0000950170-25-104971.md) | [28.5](/filings/0001193125-25-266989.md) | [27.8](/filings/0001341235-26-000010.md) | [24.3](/filings/0001341235-26-000006.md) | [9.7](/filings/0001341235-26-000010.md) |
| Total liabilities | $m | [24.3](/filings/0000950170-23-058829.md) | [28.5](/filings/0000950170-25-030102.md) | [27.9](/filings/0000950170-24-052056.md) | [27.7](/filings/0000950170-24-089238.md) | [32.2](/filings/0000950170-24-123248.md) | [33.6](/filings/0001193125-26-083012.md) | [29.6](/filings/0000950170-25-071602.md) | [29.7](/filings/0000950170-25-104971.md) | [28.6](/filings/0001193125-25-266989.md) | [27.8](/filings/0001341235-26-000010.md) | [24.3](/filings/0001341235-26-000006.md) | [9.7](/filings/0001341235-26-000010.md) |
| Long-term debt | $m | [2.7](/filings/0000950170-23-058829.md) | [0.0](/filings/0000950170-25-030102.md) | [0.0](/filings/0000950170-24-052056.md) | [0.0](/filings/0000950170-24-089238.md) | [15.0](/filings/0000950170-24-123248.md) | [15.0](/filings/0001193125-26-083012.md) | [15.1](/filings/0000950170-25-071602.md) | [0.0](/filings/0000950170-25-104971.md) | [0.0](/filings/0001193125-25-266989.md) | [0.0](/filings/0001341235-26-000006.md) | [0.0](/filings/0001341235-26-000006.md) | not reported |
| Current portion of debt | $m | [13.5](/filings/0000950170-23-058829.md) | [15.1](/filings/0000950170-25-030102.md) | [15.2](/filings/0000950170-24-052056.md) | [15.2](/filings/0000950170-24-089238.md) | [0.3](/filings/0000950170-24-123248.md) | [0.0](/filings/0001193125-26-083012.md) | [0.0](/filings/0000950170-25-071602.md) | [15.1](/filings/0000950170-25-104971.md) | [15.2](/filings/0001193125-25-266989.md) | [15.2](/filings/0001341235-26-000010.md) | [15.3](/filings/0001341235-26-000006.md) | [0.0](/filings/0001341235-26-000010.md) |
| Shareholders' equity | $m | [123](/filings/0000950170-24-123248.md) | [120](/filings/0001193125-26-083012.md) | [113](/filings/0000950170-25-104971.md) | [98.3](/filings/0001193125-25-266989.md) | [85.1](/filings/0001193125-25-266989.md) | [71.0](/filings/0001341235-26-000010.md) | [63.6](/filings/0001341235-26-000010.md) | [55.3](/filings/0001341235-26-000010.md) | [49.2](/filings/0001193125-25-266989.md) | [44.3](/filings/0001341235-26-000010.md) | [42.2](/filings/0001341235-26-000010.md) | [37.9](/filings/0001341235-26-000010.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(8.0) d](/filings/0000950170-24-123248.md) | [0.5 d](/filings/0000950170-25-030102.md) | [(10.0)](/filings/0000950170-25-071602.md) | [(13.2) d](/filings/0000950170-25-104971.md) | [(8.0) d](/filings/0001193125-25-266989.md) | [(12.0) d](/filings/0001193125-26-083012.md) | [(12.5)](/filings/0001341235-26-000006.md) | [(8.6) d](/filings/0001341235-26-000010.md) | [(7.0) d](/filings/0001193125-25-266989.md) | [(5.3) d](/filings/0001193125-26-083012.md) | [(5.1)](/filings/0001341235-26-000006.md) | [(4.6) d](/filings/0001341235-26-000010.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-23-058829.md) | [0.0 d](/filings/0000950170-24-027933.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [58.5](/filings/0000950170-23-058829.md) | [58.8](/filings/0000950170-24-052056.md) | [58.8](/filings/0000950170-24-089238.md) | [59.0](/filings/0000950170-24-123248.md) | [59.4](/filings/0000950170-25-071602.md) | [59.4](/filings/0000950170-25-104971.md) | [59.5](/filings/0001193125-25-266989.md) | [59.9](/filings/0001341235-26-000006.md) | [60.0](/filings/0001341235-26-000010.md) | [60.1](/filings/0001193125-25-266989.md) | [60.3](/filings/0001341235-26-000006.md) | [60.3](/filings/0001341235-26-000010.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 60,326,421 at 2026-08-04, from the cover of the [10-Q filed 2026-08-06](/filings/0001341235-26-000010.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:37 ET. No prices; not investment advice.